title: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.
abstract: BACKGROUND
  A positive relationship has generally been observed between plasma estrogen levels and breast cancer risk in postmenopausal women, but most of these studies have been small and few have evaluated specific estrogen fractions (such as percent bioavailable estradiol). In addition, few studies have evaluated plasma androgen levels in relation to breast cancer risk, and their results have been inconsistent. We prospectively evaluated relationships between sex steroid hormone levels in plasma and risk of breast cancer in postmenopausal women by use of a case-control study nested within the Nurses' Health Study.
  
  
  METHODS
  Blood samples were collected during the period from 1989 through 1990. Among postmenopausal women not using hormone replacement therapy at blood collection (n = 11,169 women), 156 women were diagnosed with breast cancer after blood collection but before June 1, 1994. Two control subjects were selected per case subject and matched with respect to age, menopausal status, month and time of day of blood collection, and fasting status at the time of blood collection.
  
  
  RESULTS
  From comparisons of highest and lowest (reference) quartiles, we observed statistically significant positive associations with risk of breast cancer for circulating levels of estradiol (multivariate relative risk [RR] = 1.91; 95% confidence interval [CI] = 1.06-3.46), estrone (multivariate RR = 1.96; 95% CI = 1.05-3.65), estrone sulfate (multivariate RR = 2.25; 95% CI = 1.23-4.12), and dehydroepiandrosterone sulfate (multivariate RR = 2.15; 95% CI = 1.11-4.17). We found no substantial associations with percent free or percent bioavailable estradiol, androstenedione, testosterone, or dehydroepiandrosterone. The positive relationships were substantially stronger among women with no previous hormone replacement therapy.
  
  
  CONCLUSIONS
  Our data, in conjunction with past epidemiologic and animal studies, provide strong evidence for a causal relationship between postmenopausal estrogen levels and the risk of breast cancer.
authors.affiliation: Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Hankinson
authors.forename: W C
authors.initials: WC
authors.lastname: Willett
authors.forename: J E
authors.initials: JE
authors.lastname: Manson
authors.forename: G A
authors.initials: GA
authors.lastname: Colditz
authors.forename: D J
authors.initials: DJ
authors.lastname: Hunter
authors.forename: D
authors.initials: D
authors.lastname: Spiegelman
authors.forename: R L
authors.initials: RL
authors.lastname: Barbieri
authors.forename: F E
authors.initials: FE
authors.lastname: Speizer
mesh_terms: D000328:Adult; D000368:Aged; D000728:Androgens / Q000097:blood*; D001682:Biological Availability; D001943:Breast Neoplasms / Q000097:blood* / Q000453:epidemiology; D016022:Case-Control Studies; D015331:Cohort Studies; D004958:Estradiol / Q000493:pharmacokinetics; D004967:Estrogens / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause / Q000097:blood*; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000728:Androgens; D004967:Estrogens; D004958:Estradiol